Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder

Alcohol Use Disorder Clinical Trial

— ON-ICE  

Official title:

Oxytocin and Naltrexone: Investigation of Combined Effects on Stress- and Alcohol Cue-induced Craving in Alcohol Use Disorder - a Randomized Double-blind Placebo-controlled Parallel-group Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05093296
• Other study ID #: CIMH ON-ICE 21
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: December 2, 2021
• Est. completion date: September 27, 2023

Study information

• Verified date: March 2024
• Source: Central Institute of Mental Health, Mannheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Alcohol use disorder (AUD) is a chronic relapsing disorder. Alcohol craving, a hallmark symptom of AUD that drives relapse in patients, is only insufficiently treated by existing medication. One promising new compound is Oxytocin (OXY), which showed beneficial effects on alcohol craving in preliminary clinical studies. Additionally, OXY seems to enhance effects of established medication, specifically Naltrexone (NTX), an opioid-antagonist which is approved for AUD treatment via positive synergism on neurotransmitter levels. The proposed two-armed, 1:1 randomized, double-blind, parallel group trial seeks to test the putative synergistic effects of combined intranasal OXY spray (24 IU) + oral NTX (50mg) against Placebo spray + oral NTX (50mg) on alcohol craving (primary outcome) in male and female patients with AUD that suffer from high alcohol craving, within the framework of a validated alcohol cue-and stress-exposure task (i.e. a combined Trier Stress Test and alcohol cue-exposure) that was established for screening new medications in AUD and determine their effects on craving and relapse risk. Treatment effects on additional neurobiological and biochemical markers of craving that show strong associations to individual relapse risk, will serve as secondary outcomes. Collection and analysis of follow-up data (90 days) will be performed to determine whether treatment effects relate to patient outcome.

The clinical trial period for an individual participant consists of a screening visit (visit 1), a baseline visit (visit 2) and two treatment visits (visits 3 and 4)(all within equal or less than ten days) followed by a 90 days (+/- 7 days) follow-up phase with two visits (visits 5 and 6) at day 30 (± 7 days) and day 90 (± 7 days). Visits 1 to 4 will be conducted while participants are undergoing standard in-patient treatment at the Department of Addictive Behavior and Addiction medicine at the Central Institute of Mental Health (CIMH) in Mannheim, Germany, for the medical condition under investigation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: September 27, 2023
• Est. primary completion date: July 15, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Age between 18 and 70 years

• Patients meeting the diagnosis of an alcohol dependence according to the Internation Clasification of Diseases 10th revision (ICD10)

• Patients with at least moderate craving, i.e. either >=15 points on the Alcohol Urge Questionnaire (AUQ, range 8 to 56 points) craving scale or increase in AUQ scores by >= 50% after exposure to visual alcohol cues (i.e. minimum increase of >=4 points after cue exposure)

• Ability of the individual to understand the character and the individual consequences of the clinical trial

• Written informed consent (must be available before enrollment in the study)

• Consent to random assignment

• For women with childbearing potential, use of a highly effective birth control method until 24 hours after Visit 4 and negative pregnancy test

Exclusion Criteria:

• Subjects presenting with any of the following criteria will not be included in the clinical trial: Current psychotic or bipolar disorder or current severe depressive episode with suicidal ideations

• Current treatment with any of the following substances: Any investigational medicinal product, Opioid-containing Analgesics, Anorexics, Anticonvulsants, Opioid-containing Antidiarrheal Agents, Antineoplastics, Antipsychotics (exception: episodic use of melperone, pipamperone and quetiapine are allowed), Antidepressants (exception: allowed, when being taken in stable dose for a minimum of 14 days prior to enrolment and/or doxepin in low doses [max. 75mg daily]), Opioid-containing Cough/cold agents, systemic Steroids

• Positive drug screening (amphetamines/ecstasy, opiates, cocaine, barbiturates)

• Pregnancy, lactation or breastfeeding

• Current severe somatic comorbidities: liver cirrhosis [CHILD B or C] or impaired renal function [glomerular filtration rate (GFR)<15ml/Min] [each determined by physical examination and/or laboratory testing], severe heart insufficiency [determined by assessment of medical history], pre-existing epilepsy [determined by assessment of medical history], long-QT syndrome or cardial arrhythmia [determined by ECG]

• History of hypersensitivity to the investigational medicinal product Oxytocin (Syntocinon®) and/or Naltrexone (trade names: Adepend, Naltrexon-Hcl neuraxpharm, Naltrexonhydrochlorid Accord) or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product Oxytocin (Syntocinon®) and/or Naltrexone

• Participation in other clinical trials or observation period of competing clinical trials, respectively.

• Acute suicidal tendency or acute endangerment of self and others

Related Conditions & MeSH terms

• Alcohol Addiction
• Alcohol Drinking
• Alcohol Use Disorder
• Alcoholism

Intervention

Drug:
• Oxytocin nasal spray
24 I.U. Oxytocin nasal Spray will be administered twice on two separate trial days.
• Naltrexone Pill
All participants will receive 50mg Naltrexone daily as oral tablet throughout the study
• Placebo
Placebo nasal spray (same composition as the verum oxytocin spray except for the active ingredient oxytocin)

Locations

Country	Name	City	State
Germany	Central Institute of Mental Health	Mannheim

Sponsors (4)

Lead Sponsor	Collaborator
Central Institute of Mental Health, Mannheim	German Federal Ministry of Education and Research, Heidelberg University - Coordination Centre for Clinical Trials (KKS) of Heidelberg University, Heidelberg University - Institute of Medical Biometry (IMBI)

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Alcohol Urge Questionnaire (AUQ)	Subjective Alcohol Craving will be assessed at separate time points before and after Oxytocin Administration using the AUQ	60 minutes after oxytocin/placebo application and directly after the combined stress- and cue-exposure will serve as primary outcome measure at Visit 3
Secondary	Alcohol Urge Questionnaire (AUQ)	Subjective Alcohol Craving will be assessed at separate time points before and after Oxytocin Administration using the AUQ	35 minutes after oxytocin/placebo application at Visit 3
Secondary	Alcohol Urge Questionnaire (AUQ)	Subjective Alcohol Craving will be assessed at separate time points before and after Oxytocin Administration using the AUQ	70 minutes after oxytocin/placebo application at Visit 3
Secondary	Alcohol Urge Questionnaire (AUQ)	Subjective Alcohol Craving will be assessed at separate time points before and after Oxytocin Administration using the AUQ	80 minutes after oxytocin/placebo application at Visit 3
Secondary	Alcohol Urge Questionnaire (AUQ)	Subjective Alcohol Craving will be assessed at separate time points before and after Oxytocin Administration using the AUQ	90 minutes after oxytocin/placebo application at Visit 3
Secondary	Alcohol Urge Questionnaire (AUQ)	Subjective Alcohol Craving will be assessed at separate time points before and after Oxytocin Administration using the AUQ	85 minutes after oxytocin/placebo application, i.e. directly fMRI session at Visit 4
Secondary	Primary Appraisal secondary Appraisal Scale (PASA)	Perceived stress will be assessed using the Primary Appraisal secondary Appraisal Scale (PASA) at separate time points before and after Oxytocin Administration using the AUQ at Visit 3 and Visit 4	35 minutes after oxytocin/placebo application at Visit 3
Secondary	Primary Appraisal secondary Appraisal Scale (PASA)	Perceived stress will be assessed using the Primary Appraisal secondary Appraisal Scale (PASA) at separate time points before and after Oxytocin Administration using the AUQ at Visit 3 and Visit 4	60 minutes after oxytocin/placebo application at Visit 3
Secondary	Primary Appraisal secondary Appraisal Scale (PASA)	Perceived stress will be assessed using the Primary Appraisal secondary Appraisal Scale (PASA) at separate time points before and after Oxytocin Administration using the AUQ at Visit 3 and Visit 4	90 minutes after oxytocin/placebo application at Visit 3
Secondary	Primary Appraisal secondary Appraisal Scale (PASA)	Perceived stress will be assessed using the Primary Appraisal secondary Appraisal Scale (PASA) at separate time points before and after Oxytocin Administration using the AUQ at Visit 3 and Visit 4	85 minutes after oxytocin/placebo application, i.e. directly fMRI session at Visit 4
Secondary	Positive and Negative Affect Schedule (PANAS)	Positive and Negative Affect will be assessed using the Positive and Negative Affect Schedule (PANAS) at separate time points before and after Oxytocin Administration using the AUQ at Visit 3 and Visit 4	60 minutes after oxytocin/placebo application at Visit 3
Secondary	Positive and Negative Affect Schedule (PANAS)	Positive and Negative Affect will be assessed using the Positive and Negative Affect Schedule (PANAS) at separate time points before and after Oxytocin Administration using the AUQ at Visit 3 and Visit 4	85 minutes after oxytocin/placebo application, i.e. directly fMRI session at Visit 4
Secondary	Cortisol	Cortisol plasma levels will be determined using validated Enzyme-linked Immunosorbent Assay (ELISA) methods by the central laboratory at visit 3 after Oxytocin/Placebo administration	65 minutes after oxytocin/placebo application at Visit 3
Secondary	Oxytocin	Oxytocin plasma levels will be determined using validated ELISA methods by the central laboratory at visit 3 after Oxytocin/Placebo administration	30 minutes after oxytocin/placebo application at Visit 3
Secondary	Oxytocin	Oxytocin plasma levels will be determined using validated ELISA methods by the central laboratory at visit 3 after Oxytocin/Placebo administration	65 minutes after oxytocin/placebo application at Visit 3
Secondary	Alcohol Cue-induced neural brain activation during an Alcohol cue-reactivity functional magnetic resonance imaging (fMRI) task	Neural brain activation in the mesocorticolimbic system (whole-brain and Region-of-Interest Analyses (ROIs): ventral striatum, dorsal striatum, insula), measured using the blood oxygenated level dependent (BOLD) response, during presentation of alcohol cues will serve as secondary outcome	During fMRI session at Visit 4, i.e. 40 to 85 minutes after Oxytocin/Placebo administration
Secondary	Neural Activation during a natural reward cue-reactivity fMRI task	Neural brain activation in the mesocorticolimbic system (whole-brain and ROIs: ventral striatum, dorsal striatum, insula), measured using the blood oxygenated level dependent (BOLD) response during the presentation of natural reward cues will serve as secondary outcome	During fMRI session at Visit 4, i.e. 40 to 85 minutes after Oxytocin/Placebo administration
Secondary	Neural Activation during a Face-matching fMRI task	Neural brain activation in the mesocorticolimbic system (whole-brain and ROIs: ventral striatum, dorsal striatum, insula, amygdala), measured using the blood oxygenated level dependent (BOLD) response during the presentation of emotional faces and neutral shapes will serve as secondary outcome	During fMRI session at Visit 4, i.e. 40 to 85 minutes after Oxytocin/Placebo administration
Secondary	Neural Activation during a Stop Signal fMRI Task	Neural brain activation in the mesocorticolimbic system (whole-brain and ROIs: ventral striatum, dorsal striatum, insula, dlPFC), measured using the blood oxygenated level dependent (BOLD) response during a stop signal fMRI task will serve as secondary outcome	During fMRI session at Visit 4, i.e. 40 to 85 minutes after Oxytocin/Placebo administration
Secondary	Adverse Events (AEs)/Serious Adverse Events (SAEs) and Discontinuation rate	Rate of adverse events, serious adverse events and rate of discontinuation of the study due to an adverse event	During Study Visits 1 to 6, including the 90 day (±7 day) follow-up period
Secondary	Subjective quality of life index	Quality of life will be assessed using the WHO-QOL-BREF scores	At Visit 5, i.e. 30 days (+/- 7 days) after Visit 3
Secondary	Subjective quality of life index	Quality of life will be assessed using the World Health Organization (WHO) Quality of life assessment (WHO-QOL-BREF) scores	At Visit 6, i.e. 90 days (+/- 7 days) after Visit 3
Secondary	Time to relapse during the follow-up period of 90 days (+/- 7 days)	Time from randomization to relapse to alcohol use (in days)	During 90-day (± 7 days) Follow-up
Secondary	Cumulative alcohol consumption during the follow-up period of 90 days (+/- 7 days)	Self-reported cumulative alcohol use (in gram)	During 90-day (± 7 days) Follow-up
Secondary	Percent heavy drinking days during the follow-up period of 90 days (+/- 7 days)	Self-reported percent heavy drinking days (in %)	During 90-day (± 7 days) Follow-up